Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr 28:10:21.
doi: 10.1186/1471-2172-10-21.

Induction of mast cell accumulation, histamine release and skin edema by N49 phospholipase A2

Affiliations

Induction of mast cell accumulation, histamine release and skin edema by N49 phospholipase A2

Ji-Fu Wei et al. BMC Immunol. .

Abstract

Background: It has been recognized that phospholipase A2 (PLA2) is a crucial component of snake venom, which contributes greatly to snake venom induced inflammation in man. However, the mechanisms through which N49 PLA2 provoke inflammation remain unclear. Recently, a N49 PLA2, TM-N49 from Protobothrops mucrosquamatus crude venom was characterized in our laboratory. Since the purification procedure developed is able to supply us with relatively large quantity of highly purified TM-N49, we investigated the ability of TM-N49 in induction of inflammation.

Results: The results showed that TM-N49 provoked a dose dependent increase in microvascular leakage in the skin of rats. The potency of TM-N49 in induction of skin edema appeared similar potency of bradykinin and histamine. Pretreatment of rats with compound 48/80 diminished TM-N49 induced skin reaction and reduced mast cell numbers in rats. Ginkgolide B and cyproheptadine, but not terfenadine and quinacrine, inhibited TM-N49 elicited microvascular leakage when they were co-injected with the stimulus to rat skin. Moreover, TM-N49 was found to induce histamine release from human colon, lung and tonsil mast cells, and both metabolic inhibitors and pertussis toxin were capable of inhibiting TM-N49 elicited histamine release. TM-N49 induced mast cell accumulation in the peritoneum of mice, which was inhibited by co-injection of ginkgolide B, cyproheptadine and terfenadine. Intravenous injection of monoclonal antibodies against CD18, ICAM-1 and CD11a also blocked TM-N49 induced mast cell accumulation.

Conclusion: TM-N49 is a potent stimulus for skin edema, mast cell activation and accumulation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of TM-N49 on rat dermal microvascular leakage. Various doses of TM-N49 were injected into the skin of rat for 20 min. Also shown are the responses to BSA, bradykinin and histamine alone at a dose of 5 μg and normal saline control. Skin reaction represented the area of Evan's blue extravasation. Data are displayed as a boxplot, which indicates the median, interquartile range, the largest and smallest values other than outliers (O) (defined as those which are more than 1.5 box lengths from the median) for 6 animals in each group. * P < 0.05 compared with the response to the diluent only control animals.
Figure 2
Figure 2
Influence of compound 48/80 on rat dermal microvascular leakage induced by TM-N49 and histamine (A), and on mast cell numbers in the peritoneum of rats (B). Rats were intra-peritoneally injected with compound 48/80 at a dose of 0.6 mg·kg-1 for 6 h, twice a day for 3 days, and doubled dose in day 4 before TM-N49 (5 μg) or histamine (5 μg) being administrated for 20 min. Skin reaction represented the area of Evan's blue extravasation. Data are displayed as a boxplot, which indicates the median, interquartile range, the largest and smallest values other than outliers (O) (defined as those which are more than 1.5 box lengths from the median) for 6 animals in each group. In (A), * P < 0.05 compared with the corresponding response to untreated animals and in (B), * P < 0.05 compared with the response to untreated animals.
Figure 3
Figure 3
Influence of anti-inflammatory drugs on rat dermal microvascular leakage induced by TM-N49 (5 μg), bradykinin (5 μg), PAF (5 μg) and histamine (5 μg). Ginkgolide (GG, 5 μg), cyproheptadine (CH, 5 μg), terfenadine (TF, 5 μg) or quinacrine (QC, 5 μg) were co-injected with TM-N49, bradykinin or histamine, respectively for 20 min, whereas PAF was only co-injected with GG. Skin reaction represented the area of Evan's blue extravasation. Data are displayed as a boxplot, which indicates the median, interquartile range, the largest and smallest values other than outliers (O) (defined as those which are more than 1.5 box lengths from the median) for 6 animals in each group. * P < 0.05 compared with the response to the corresponding uninhibited control animals.
Figure 4
Figure 4
Effects of TM-N49 on histamine release from colon, lung and tonsil mast cells in the presence or absence of exogenous calcium and magnesium. The values shown are mean ± SE for four to five separate experiments. Various concentrations of TM-N49 were incubated with cells for 15 min before termination of the reactions. * P < 0.05 compared with the response to the corresponding buffer alone group, P < 0.05 compared with the response to the corresponding group in the absence of calcium and magnesium.
Figure 5
Figure 5
Time course for histamine release from colon, lung and tonsil mast cells induced by TM-N49 (30 μg/ml), anti-IgE antibody (10 μg/ml) and calcium ionophore (1 μg/ml). The values shown are mean ± SE of the percentage of maximum histamine release, which equals (actual net histamine release/maximum net histamine release induced by the testing compound) × 100%, for four to five separate experiments.
Figure 6
Figure 6
Effect of TM-N49 (TM) on mast cell numbers in mouse peritoneum. Various doses of TM-N49 were injected into the peritoneum of mice for 10 min, 2 h, 6 h or 16 h. Also shown are the responses to BSA and normal saline control. Data are displayed as a boxplot, which indicates the median, interquartile range, the largest and smallest values other than outliers (O) (defined as those which are more than 1.5 box lengths from the median) for 6 animals in each group. * P < 0.05 compared with the response to the corresponding diluent only control animals.

Similar articles

Cited by

References

    1. Verheij HM. In: Phospholipases in clinical inflammation. Glaser KB, Vadas P, editor. Boca Raton FL: CRC Press; 1996. pp. 3–24.
    1. Dennis EA. In: The enzymes. Boyer PD, editor. New York: Academic Press; 1983. pp. 307–353.
    1. Dufton MJ, Eaker D, Hider RC. Conformational properties of phospholipases A2. Secondary-structure prediction, circular dichroism and relative interface hydrophobicity. Eur J Biochem. 1983;137:537–544. doi: 10.1111/j.1432-1033.1983.tb07859.x. - DOI - PubMed
    1. Maraganore JM, Merutka G, Cho W, Welches W, Kézdy FJ, Heinrikson RL. A new class of phospholipases A2 with lysine in place of aspartate 49. Functional consequences for calcium and substrate binding. J Biol Chem. 1984;259:13839–13843. - PubMed
    1. Maraganore JM, Heinrikson RL. The lysine-49 phospholipase A2 from the venom of Agkistrodon piscivorus piscivorus. Relation of structure and function to other phospholipases A2. J Biol Chem. 1986;261:4797–4804. - PubMed

Publication types

MeSH terms